Hospital for Special Surgery
New York, 10021, United States
Location status: Recruiting
NCT Number: NCT05981105
The goal of this interventional clinical trial is to assess opioid consumption 24-48 hrs post anesthesia block among patients undergoing total knee arthroplasty. The main question it aims to answer is:
1. Is there a difference in opioid consumption 24-48 hours post block administration among patients that receive an adductor canal catheter (ACC) versus adductor canal block (ACB)?
Participants will be:
* Randomized to receive an adductor canal catheter (ACC) or a sham adductor canal catheter. * Asked to use the Diagnotes application to communicate with the pain doctor while the catheter is in place. * Follow up for up to 6 months post-operation. Researchers will compare the interventional group (ACC) to the control group (sham ACC + ACB) to see if there is difference in opioid consumption and chronic pain at 6 months post-operation.
Interested in participating?
Request Info18 year–75 year
All sexes
Interventional
Not applicable
New York, 10021, United States
Location status: Recruiting
The purpose of this study is to see if adding a continuous ACB catheter will extend analgesia beyond the 24-48 hour period. This interventional clinical trial will assess opioid consumption in patients undergoing total knee arthroplasty 24 to 48 hours after anesthesia block. Rebound pain is a well-known phenomenon in which patients experience severe pain immediately after the nerve block is removed. It is also known that by extending the duration of analgesia, you can reduce or prevent rebound pain. Motor sparing compartment blocks have transformed patients' ability to participate in rehabilitation earlier than ever before, even ambulating on POD 0. Thus, by extending analgesia and encouraging early ambulation, adductor canal catheters are likely to not only reduce opioid consumption but also allow for earlier discharge. The two "hot" themes in recent total knee replacement analgesia pathways are not only providing an effective Enhanced recovery after surgery (ERAD) protocol, but also combating the opioid epidemic through regional anesthesia and non-opioid multimodal pathways. This study will assist in determining which modality is superior (single shot blocks with additive versus catheter) and will introduce a novel method of following patients at home via a transitional pain service (telemedicine). This research will further investigate chronic pain 6 months after surgery.
Patients in the intervention group will have a catheter that continuously infuses numbing medication into their operative leg for 50 hours (up to POD 3). It is hypothesized that the patient will have better pain control, mobility, and less rebound pain, which is common following POD 1. By infusing the catheter with a disposable single use ambIT system (Summit Medical Products), all patients enrolled in the intervention group (ACC) will have the same amount running continuously, allowing the patient to be discharged with the catheter in place before the 50-hour infusion is completed. Prior to discharge, patients will be instructed on how to remove the catheter and will be able to download the Smartphone app "Diagnotes" at the hospital. While the catheter is in place, the Diagnotes app (a HIPPA-compliant text messaging service) will be the patient's primary means of communication with the pain doctor at home.
Patients in the control group will have a sham (fake) catheter attached to their operative leg for 50 hours. Patients will also be instructed on how to remove the catheter prior to discharge and will be able to download the Smartphone app "Diagnotes" in the hospital. While the catheter is in place, the Diagnotes app (a HIPPA-compliant text messaging service) will be the patient's primary means of communication with the pain doctor at home.
Researchers will contact both groups for follow-ups for up to 6 months.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
0.2% ropivacaine will be infused through a catheter pump at a rate of 10 ml/hr, 600 ml reservoir.
sham catheter with no infusion
Time frame: from 24 hours to 48 hours
The cumulative opioid consumption 24-48 hours post block administration. Measured in morphine milligram equivalents per day.
Although collected over a period of time, the total amount will be summed and the average will be reported.
Time frame: 72 hours to 1 week
The cumulative opioid consumption 72hours, 96 hours, and 1 week post block administration. Measured in morphine milligram equivalents per day.
Although collected over a period of time, the total amount will be summed and the average will be reported.
Time frame: Day of surgery to post operative day (POD) 60
Patients are asked to give a number between 0 and 10 that best fits their pain intensity. The scale is 0 = 'no pain at all' whereas 10 = 'the worst pain ever possible'.
Measured at multiple time points: DOS, post-operative day (POD) 1, POD 2, POD 3, POD 4, POD 7, & POD 60
Time frame: post operative day (POD) 1 up to POD 4
Collected from the physical therapy notes. This outcome will assess for time to ambulation (measured in distance traveled, stairs, time of ambulating > 30 meters, and reaching discharge criteria).
Time frame: post operative day (POD) 1, 2, 4 & 60
Patients are asked to report on their satisfaction with pain control on a scale of 0 to 10, with 0 = extremely dissatisfied and 10 = extremely satisfied.
Time frame: up to 7 days after the day of surgery
From when the patient is in the PACU to when the patient has been discharged from the hospital. PACU time = "PACU Transfer In" and Discharge time = "Discharge"
Time frame: after the surgery end time, on post operative day (POD) 1, 4, and 60
The Opioid-Related Symptom Distress Scale (ORSDS) is a 4-point scale that evaluates 3 symptom distress dimensions (frequency, severity, bothersomeness) for 12 symptoms. The symptom-specific ORSDS is the average of the 3 symptom distress dimensions. The composite ORSDS is the average of 12 symptom-specific scores.
Time frame: On post operative day (POD) 1, 2, 3, 4
Whether a participant experiences buckling, falls, or quadricep weakness during physical therapy, precluding ambulation.
Time frame: During surgery
Whether the participant experienced any blood loss during their surgical procedure.
Measured in binary responses (yes/no).
Time frame: Up to post operative day 3
The patient will be asked in the morning of POD 1 when they feel the block has worn off, and in the evening of POD 3 after the catheter has been removed.
Time frame: post operative day (POD) 0,1,2,3,4
The total distance of ambulation during physical therapy while the patient is inpatient, collected from the physical therapy notes.
Time frame: up to post operative day 4
Patient will be asked if they have experience any of the following with regards to the catheter:
delayed weakness, unintentional dislodgment, leakage, catheter infection, dysesthesias, falls, LAST
Time frame: 3 month after surgery
Whether the patient was readmitted to a hospital for additional pain control.
Time frame: up to post operative day 4
Patients will report if they experience any block complications including, neuropraxia (saphenous), transient palsies: peroneal, tibial nerve.
Time frame: before surgery and up to post operative day 60
The survey asks for patients' view about their knee, such as how they feel about their knee and how well they are able to do usual activities. Choices on each question are: none, mild, moderate, severe, extreme
Time frame: 6 weeks
Patient will be asked about their range of motion (flexion ROM and Extension ROM). Data collected from surgeon's note
Time frame: up to post operative day 60
The SF-36 measures includes the following: physical functioning (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MH).
Measured on a scale of 1 to 3, with 1 = "yes limited a lot", 2 = "yes limited a little", 3 = "no not limited at all".
The total score for each participant is calculated and then all the scores are average across all participants.
Time frame: at 3 months & 6 months
The Leeds Assessment of Neuropathic Symptoms and Signs Pain Scale (LANSS) comprises of a 7-item pain scale, including the sensory descriptors and items for sensory examination.
Out of the seven items in the Leeds Assessment of Neuropathic Symptoms and Signs Pain Scale (LANSS), five are symptom related and two are examination items.
If patient reports surgery-related pain greater than 3 on the NRS at the 3 months and 6 months postoperative visit, patient will complete this questionnaire.
Time frame: at 3 months & 6 months
The Current Opioid Misuse Measure (COMM) is a commonly used self-report instrument to identify and monitor aberrant opioid-related behavior in chronic pain patients on opioid therapy.
At the 3 months and 6 months postoperative visit, if patients are still being prescribed opioids, patient will be asked to fill out the questionnaire
Choices on the questionnaire are:
never, seldom, sometimes, often, very often
Time frame: up to post operative day 4
Research staff will mark if patients contacted the pain doctor via the Diagnotes application.
Time frame: up to post operative day 7
Patients will be asked at 1 week post-operation, about their pain medication usage (how many pills of your opioid medication do you have left?)
Time frame: before the surgery and up to post operative day 60
The Pain Catastrophizing Scale (PCS) assesses the extent of catastrophic thinking due to low back pain according to 3 components: rumination, magnification, and helplessness. It is a 13-item scale, with a total range of 0 to 52. Higher scores are associated with higher amounts of pain catastrophizing.
Time frame: 3 months & 6 months
The Pain Disability Index (PDI) is a widely-used instrument to measure pain-related disability.
Scoring: Scores are assigned based on an 11-point scale ranging from 0 (no disability) to 10 (total disability). Scores range from 0 to 70. The higher the index the greater the person's disability due to pain.
Time frame: up to post operative day 2
Patient and research staff will report which group they believe the patient was randomized to.
Time frame: up to post operative day 4
Data on whether patient experienced quadriceps weakness and foot drop during physical therapy. Collected from physical therapy notes.
Time frame: up to post operative day 60
Research staff will document any non-opioid pain medications (lyrica, robaxin, tyelnol, etc) taken by each participant. Medications may be given at the discretion of the APS service.
Time frame: up to post operative day 7
Research staff will document if patient received IV PCA during their stay at the hospital. Measured in morphine equivalent.
Discharge times can vary from participant to participant (from POD 0 up until POD 2)
Time frame: During the surgical procedure
The time it takes for the patient to be induced. Measured from induction start to induction end.
Times for each participants will be calculated (in minutes) and then average across all participants.
Time frame: During the surgical procedure
The total time to use a tourniquet. Measured from tourniquet inflated time tourniquet deflated time.
Times for each participants will be calculated (in minutes) and then average across all participants.
Contact information is provided by the study sponsor or research team.
Pa Thor, PhD
CONTACT
Stavros Memtsoudis, MD/PhD
CONTACT
Hospital for Special Surgery, New York
Other
Expanding the Peri-operative Surgical Home Model: ERAS TKR With a Transitional Pain Service (TeleTPS) - Continuous Adductor Canal Catheter Versus Adductor Canal Block for Total Knee Arthroplasty, a Randomized Double-blinded Controlled Trial.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05905419
Chronic Pain, Fibromyalgia
Durham, North Carolina, United States
View Trial DetailsNCT07561411
Chronic Pain, Hemic and Lymphatic Diseases
Beirut, Lebanon
View Trial DetailsNCT03675386
Chemically-Induced Disorders, Chronic Pain
Toronto, Ontario, Canada
View Trial DetailsNCT06345872
Chronic Insomnia, Chronic Pain
Tampa, Florida, United States
View Trial Details